ALEXION PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1992-01-01
- Employees
- 3.8K
- Market Cap
- -
- Website
- http://www.alexion.com
Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
- Conditions
- First Posted Date
- 2005-07-22
- Last Posted Date
- 2006-12-04
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT00122330
- Locations
- 🇺🇸
University of California at Los Angeles, Los Angeles, California, United States
🇺🇸Washington University School of Medicine, Dept. of Internal Medicine/Division of Hematology, St. Louis, Missouri, United States
🇺🇸Presbyterian Medical Center, PENN Comprehensive Hemophilia & Thrombosis Program, Philadelphia, Pennsylvania, United States
Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)
- First Posted Date
- 2005-07-22
- Last Posted Date
- 2018-03-13
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 187
- Registration Number
- NCT00122317
- Locations
- 🇺🇸
Hartford Hospital, Cancer Clinical Research Office, Hartford, Connecticut, United States
🇺🇸Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇦🇺The Royal Perth Hospital, Department of Haematology/Level 2, Perth, Western Australia, Australia
Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab
- Conditions
- First Posted Date
- 2005-07-22
- Last Posted Date
- 2007-02-21
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 85
- Registration Number
- NCT00122304
- Locations
- 🇺🇸
NYU Clinical Cancer Center, New York, New York, United States
🇺🇸Johns Hopkins University Medical Center, Baltimore, Maryland, United States
🇺🇸Presbyterian Medical Center, PENN Comprehensive Hemophilia & Thrombosis Program, Philadelphia, Pennsylvania, United States
Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
- Conditions
- First Posted Date
- 2004-07-23
- Last Posted Date
- 2018-02-22
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 4000
- Registration Number
- NCT00088179
- Locations
- 🇺🇸
Bakersfield Heart Hospital, Bakersfield, California, United States
🇺🇸St. Vincent's Medical Center, Bridgeport, Connecticut, United States
🇺🇸Medical Center of Central Georgia, Macon, Georgia, United States
Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardio-Pulmonary Bypass
- Conditions
- First Posted Date
- 2002-10-31
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 3000
- Registration Number
- NCT00048308
- Locations
- 🇺🇸
Northside Hospital ans Heart Institute, St. Petersburg, Florida, United States
🇺🇸University of Illinois - Chicago, Chicago, Illinois, United States
🇺🇸Sparks Regional Medical Center, Fort Smith, Arkansas, United States
Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B
- Conditions
- First Posted Date
- 2002-06-25
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 85
- Registration Number
- NCT00040144
- Locations
- 🇨🇳
Clinical Trial Site, Hong Kong, China
Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With HIV Infection and Modestly Detectable Viral Load.
- Conditions
- First Posted Date
- 2002-06-25
- Last Posted Date
- 2015-12-30
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT00040157
- Locations
- 🇺🇸
Stony Brook University Infectious Disease, Dept. of Medicine, Stony Brook, New York, United States
🇺🇸Community Health Care Center One, Inc., Ft. Lauderdale, Florida, United States
🇺🇸St. Lukes Roosevelt Hospital, New York, New York, United States
Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With Chronic Hepatitis B Infection.
- Conditions
- First Posted Date
- 2002-05-20
- Last Posted Date
- 2009-08-19
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT00037622
Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-naive Adults With Chronic Hepatitis B Virus Infection
- Conditions
- First Posted Date
- 2002-04-29
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 79
- Registration Number
- NCT00034359
- Locations
Clinical Trial Site, Novi Sad, Former Yugoslavia